Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience.
Journal
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
ISSN: 2148-5607
Titre abrégé: Turk J Gastroenterol
Pays: Turkey
ID NLM: 9515841
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
entrez:
7
3
2020
pubmed:
7
3
2020
medline:
6
10
2021
Statut:
ppublish
Résumé
Gastric neuroendocrine tumors (G-NETs) are rare tumors, but their incidence is gradually increasing. Despite the existence of many classification systems, determining prognosis and planning treatment in patients with G-NETs remains a clinical challenge. In this study, the prognostic value of the World Health Organization (WHO) 2017 grading system and the effect of surgery on survival in low grade neuroendocrine tumors were investigated. G-NETs who were diagnosed between January 2000 and May 2017 were included in the study. Patients' demographic characteristics, treatment details, and survival data were obtained from medical charts. Pathological samples were re-classified according to the WHO 2017 grading system. Of the total 94 evaluated patients, 50 (53.2%) were classified with G1 NETs, 37(39.4%) with G2 NETs, 4(4.2%) with well-differentiated G3 NETs, and the remaining 3 patients with poorly differentiated G3 neuroendocrine carcinoma (NEC). The median follow-up time was 83.2 months. There was a statistically significant difference in 5-year progression free survival (PFS) between G1 tumors (100%) and G2 tumors (76%) (p<0.001). However, there was no statistically significant deference in 5-year overall survival rate (OS) for G1 (97%) and G2 (82%) tumors (p=0.141). When G2 and G1 NETs were compared according to their surgical approach, radical surgery was more frequently performed in patients with G2 tumors (p<0.001). However, radical surgery did not improve PFS in G1 and G2 NETs. The WHO 2017 NET classification system may have low prognostic value for determining the prognosis of patients with G1 and G2 tumors. Radical surgery for G1 and G2 NETs did not improve PFS in our study.
Sections du résumé
BACKGROUND/AIMS
Gastric neuroendocrine tumors (G-NETs) are rare tumors, but their incidence is gradually increasing. Despite the existence of many classification systems, determining prognosis and planning treatment in patients with G-NETs remains a clinical challenge. In this study, the prognostic value of the World Health Organization (WHO) 2017 grading system and the effect of surgery on survival in low grade neuroendocrine tumors were investigated.
MATERIALS AND METHODS
G-NETs who were diagnosed between January 2000 and May 2017 were included in the study. Patients' demographic characteristics, treatment details, and survival data were obtained from medical charts. Pathological samples were re-classified according to the WHO 2017 grading system.
RESULTS
Of the total 94 evaluated patients, 50 (53.2%) were classified with G1 NETs, 37(39.4%) with G2 NETs, 4(4.2%) with well-differentiated G3 NETs, and the remaining 3 patients with poorly differentiated G3 neuroendocrine carcinoma (NEC). The median follow-up time was 83.2 months. There was a statistically significant difference in 5-year progression free survival (PFS) between G1 tumors (100%) and G2 tumors (76%) (p<0.001). However, there was no statistically significant deference in 5-year overall survival rate (OS) for G1 (97%) and G2 (82%) tumors (p=0.141). When G2 and G1 NETs were compared according to their surgical approach, radical surgery was more frequently performed in patients with G2 tumors (p<0.001). However, radical surgery did not improve PFS in G1 and G2 NETs.
CONCLUSION
The WHO 2017 NET classification system may have low prognostic value for determining the prognosis of patients with G1 and G2 tumors. Radical surgery for G1 and G2 NETs did not improve PFS in our study.
Identifiants
pubmed: 32141816
doi: 10.5152/tjg.2020.18919
pmc: PMC7062132
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
91-98Références
Medicine (Baltimore). 2015 Nov;94(44):e1748
pubmed: 26554772
Neuroendocrinology. 2017;104(1):26-32
pubmed: 26731483
World J Surg. 2004 Jul;28(7):652-8
pubmed: 15383867
Aliment Pharmacol Ther. 2014 May;39(10):1071-84
pubmed: 24628514
World J Gastrointest Endosc. 2017 Apr 16;9(4):153-161
pubmed: 28465781
Int J Oncol. 2003 Dec;23(6):1687-95
pubmed: 14612942
World J Gastroenterol. 2017 Jan 21;23(3):516-524
pubmed: 28210088
J Nucl Med. 1997 Jun;38(6):853-8
pubmed: 9189129
Ann Oncol. 2010 May;21 Suppl 5:v223-7
pubmed: 20555086
Digestion. 2000;62 Suppl 1:59-68
pubmed: 10940689
Neuroendocrinology. 2016;103(2):119-24
pubmed: 26784901
J Clin Pathol. 2014 Nov;67(11):938-48
pubmed: 25053544
Am J Gastroenterol. 1998 Oct;93(10):1945-8
pubmed: 9772061
J Natl Cancer Inst. 2008 Sep 17;100(18):1282-9
pubmed: 18780869
Ann Diagn Pathol. 2017 Aug;29:11-16
pubmed: 28807335
Am J Surg Pathol. 2014 Apr;38(4):437-47
pubmed: 24503751
Scand J Gastroenterol. 2002 Feb;37(2):246-8
pubmed: 11843065
Nat Rev Endocrinol. 2011 Aug 02;8(1):54-64
pubmed: 21808296
BMC Gastroenterol. 2016 Sep 09;16:111
pubmed: 27613657
Kaohsiung J Med Sci. 2018 Nov;34(11):650-656
pubmed: 30392572
Eur J Surg Oncol. 2019 May;45(5):808-815
pubmed: 30611565
Gastroenterology. 1998 Apr;114(4):817-22
pubmed: 9516403
N Engl J Med. 2000 Aug 24;343(8):551-4
pubmed: 10954763
J Gastroenterol. 2015 May;50(5):564-72
pubmed: 25142799
J Gastrointestin Liver Dis. 2013 Mar;22(1):93-6
pubmed: 23539397
Dig Dis Sci. 2016 Mar;61(3):708-12
pubmed: 26715503
Hum Pathol. 2011 Oct;42(10):1373-84
pubmed: 21531442
Cancer. 2003 Feb 15;97(4):934-59
pubmed: 12569593
Neuroendocrinology. 2017;105(4):412-425
pubmed: 28803232
Cell Physiol Biochem. 2018;45(1):389-396
pubmed: 29402806
Medicine (Baltimore). 2016 Jul;95(30):e3977
pubmed: 27472674
Asian Pac J Cancer Prev. 2013;14(1):419-22
pubmed: 23534765
World J Gastroenterol. 2014 Jan 7;20(1):118-25
pubmed: 24415864
ScientificWorldJournal. 2012;2012:869769
pubmed: 23326217
Diagnostics (Basel). 2015 Apr 08;5(2):119-76
pubmed: 26854147
Am J Surg Pathol. 2015 May;39(5):683-90
pubmed: 25723112
Korean J Thorac Cardiovasc Surg. 2018 Apr;51(2):142-145
pubmed: 29662814